Sun Pharma faces potential impact from the US 100% tariff on patented drugs, which could reduce FY26–27 earnings by 8–10%. Generic drugs remain exempt. The company’s innovative portfolio, strong cash position, and mitigation options support steady revenue growth, maintaining HSBC’s Buy rating with Rs 1,850 target.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets